Showing results (81-90 of 182) with videos related to
Sort By:
Pageof 19
Heart & Lung : the Journal of Critical Care|April 10, 2018
Percutaneous biventricular Impella support in therapy-refractory cardiogenic shockCheng-Ying Chiu, Robert Hättasch, Damaris Praeger, et al.European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|January 8, 2017
Redo procedures for degenerated stentless aortic xenografts and the role of valve-in-valve transcatheter techniquesHerko Grubitzsch, Sebastian Zobel, Torsten Christ, et al.Journal of Molecular Medicine (Berlin, Germany)|April 29, 2009
Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular systemAntje Ludwig, Mandy Fechner, Nicola Wilck, et al.Annals of the New York Academy of Sciences|May 7, 2009
First clinical experience with intravenous recombinant human relaxin in compensated heart failureThomas Dschietzig, Sam Teichman, Elaine Unemori, et al.The Journal of Biological Chemistry|December 3, 2003
A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase-, and Akt-dependent pathway and leads to endothelial-dependent vasorelaxationMario Lorenz, Silja Wessler, Elena Follmann, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|February 1, 2007
Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activityMario Lorenz, Bernd Hewing, Jingyi Hui, et al.Clinical and Experimental Hypertension (New York, N.Y. : 1993)|May 10, 2016
Galectin-3 and prediction of therapeutic response to renal sympathetic denervationMarius Schwerg, Björn Eilers, Anja Wienecke, et al.Journal of Cardiac Failure|March 31, 2009
Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trialThomas Dschietzig, Sam Teichman, Elaine Unemori, et al.American Heart Journal Plus : Cardiology Research and Practice|May 25, 2026
Tolerability of SGLT2 inhibitors in patients with Fabry disease: An observational studyIsabel Mattig, Berit Zirkelbach, Carina Bonnekoh, et al.Neuroendocrinology|July 4, 2015
Staged Catheter-Based Valve Treatment of Severe Carcinoid Heart DiseaseMichael Laule, René Pschowski, Ulrich-Frank Pape, et al.Pageof 19